Cargando…

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

PURPOSE: Owing to its genetic heterogeneity and acquired resistance, triple-negative breast cancer (TNBC) is not responsive to single-targeted therapy, causing disproportional cancer-related death worldwide. Combined targeted therapy strategies to block interactive oncogenic signaling networks are b...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jichao, McLaughlin, Ronan P., van der Noord, Vera, Foekens, John A., Martens, John W. M., van Westen, Gerard, Zhang, Yinghui, van de Water, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797661/ https://www.ncbi.nlm.nih.gov/pubmed/31388935 http://dx.doi.org/10.1007/s10549-019-05380-z

Ejemplares similares

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
por: McLaughlin, Ronan P., et al.
Publicado: (2019)

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
por: van der Noord, Vera E., et al.
Publicado: (2019)

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression
por: He, Jichao, et al.
Publicado: (2020)

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
por: van der Noord, Vera E., et al.
Publicado: (2022)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
por: Trendowski, Matthew, et al.
Publicado: (2015)

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway
por: Xing, Xiaofang, et al.
Publicado: (2014)

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
por: Wander, Seth A., et al.
Publicado: (2013)

Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation
por: Phyu, Su Myat, et al.
Publicado: (2018)

PBI-05204, a supercritical CO(2) extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway
por: Pan, Yong, et al.
Publicado: (2014)

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
por: Ansems, Marleen, et al.
Publicado: (2015)

Dynamic Akt/mTOR Signaling in Children with Autism Spectrum Disorder
por: Onore, Charity, et al.
Publicado: (2017)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
por: Jansen, M. P. H. M., et al.
Publicado: (2011)

Co-regulated gene expression of splicing factors as drivers of cancer progression
por: Koedoot, Esmee, et al.
Publicado: (2019)

Endocan as a prognostic biomarker of triple-negative breast cancer
por: Sagara, Atsunobu, et al.
Publicado: (2016)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
por: Thakkar, A., et al.
Publicado: (2016)

Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer
por: van Gelder, Michel, et al.
Publicado: (2016)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
por: Mori, Hitomi, et al.
Publicado: (2019)

Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells
por: Liu, Qiuyu, et al.
Publicado: (2022)

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
por: Jansson, Sara, et al.
Publicado: (2018)

A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
por: Tseng, Ling-Ming, et al.
Publicado: (2017)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

Celastrol Alleviates Aortic Valve Calcification Via Inhibition of NADPH Oxidase 2 in Valvular Interstitial Cells
por: Liu, Huibing, et al.
Publicado: (2019)

Nicotinamide Mononucleotide Alleviates Cardiomyopathy Phenotypes Caused by Short-Chain Enoyl-Coa Hydratase 1 Deficiency
por: Cai, Ke, et al.
Publicado: (2022)

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
por: Girgert, Rainer, et al.
Publicado: (2012)

Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival
por: Oprea-Ilies, Gabriela, et al.
Publicado: (2012)

Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation
por: Vihervuori, H., et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
por: Siddappa, Chidananda M., et al.
Publicado: (2019)

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021)

Targeting the Lymphatic System for Interstitial Decongestion
por: Martens, Pieter, et al.
Publicado: (2021)

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
por: Bernier, Cynthia, et al.
Publicado: (2018)

Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
por: Park, Jihyun, et al.
Publicado: (2021)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

Downregulation of miR-205 contributes to epithelial–mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1–RAGE signaling pathway
por: Wang, Ling, et al.
Publicado: (2019)

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling
por: Ma, Ning, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvsum56rgahqogbvhiihhto6ef